Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pneumococcal

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

IQWiG finds some value in Pfizer’s Inlyta

Cost effectiveness body decides cancer drug has benefits over Bayer's Nexavar

- PMLiVE

FDA approves first egg-free flu vaccine Flublok

Insect virus production method means more vaccine can be produced at a faster rate

- PMLiVE

Pfizer enters ADHD market with Quillivant XR launch

Gained rights last November as part of NextWave acquisition

Janssen boosts vaccines pipeline with GlycoVaxyn deal

Research will focus on targeting multiple bacterial pathogens

- PMLiVE

Sanofi enters vaccines partnership with Sutro

Will develop products for two undisclosed targets

- PMLiVE

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

ViiV submits dolutegravir for approval to treat HIV in US, EU and Canada

GSK-Pfizer joint venture takes next step towards commercialisation

- PMLiVE

GSK’s four-strain flu vaccine debuts in the US

Fluarix Quadrivalent protects against two influenza A and two influenza B subtypes

- PMLiVE

Eliquis meets targets as long-term VTE therapy

Pfizer and BMS report positive phase III data for the Factor Xa inhibitor

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links